Peptide Bioavailability: Why Administration Route Matters

The Oral Bioavailability Problem

The gastrointestinal tract is designed to break down proteins and peptides into individual amino acids for absorption. This is excellent for nutrition but devastating for peptide therapeutics. The two main barriers are enzymatic degradation (proteases in the stomach and intestine rapidly cleave peptide bonds) and poor membrane permeability (most peptides are too large and hydrophilic to cross the intestinal epithelium).

The result: most peptides have oral bioavailability below 1-2%. A 500mcg oral dose might deliver less than 10mcg to the bloodstream. This is why the vast majority of peptide therapeutics require injection — it's the only route that consistently delivers the full dose to systemic circulation.

Notable exceptions include BPC-157 (unusually stable in gastric acid due to its gastric juice origin), oral semaglutide (Rybelsus, which uses SNAC absorption enhancer technology), and cyclosporine (a cyclic peptide with unusual lipophilicity). Each overcomes the oral barrier through different mechanisms.

Route Comparison

Subcutaneous vs Intramuscular Injection

Both routes provide near-100% bioavailability but differ in absorption kinetics. Subcutaneous (SC) injection into the fat layer under the skin provides slower, more sustained absorption — ideal for peptides where steady blood levels are desired (semaglutide, CJC-1295). Intramuscular (IM) injection provides faster absorption due to higher blood flow to muscle tissue — relevant when a rapid pulse of peptide is desired (TB-500 for acute injury).

For most research peptides, SC injection is preferred due to ease of administration (shorter needle, less painful, can self-administer) and more predictable absorption. The insulin syringe (29-31 gauge, 0.5-1 inch) is the standard tool for SC peptide injection.

Intranasal Delivery

The nasal mucosa provides a direct route to the central nervous system via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier. This makes intranasal delivery uniquely suited for neuropeptides like Semax and Selank that target the brain.

Bioavailability is typically 10-30% — lower than injection but often adequate for small, potent peptides. The nasal route avoids first-pass hepatic metabolism and provides rapid onset (5-15 minutes). Limitations include variable absorption depending on nasal congestion, limited dose volume (100-200µL per nostril), and potential for local irritation.

Emerging Oral Delivery Technologies

The pharmaceutical industry is investing heavily in oral peptide delivery, driven by the enormous commercial potential of oral GLP-1 agonists. Key technologies include:

• SNAC (Sodium N-[8-(2-Hydroxybenzoyl) Amino] Caprylate): Used in Rybelsus (oral semaglutide). Creates a local pH increase that protects the peptide and enhances absorption through the gastric mucosa.
• Orforglipron: A non-peptide small molecule that activates the GLP-1 receptor orally — circumventing the bioavailability problem entirely by being a small molecule rather than a peptide.
• Permeation enhancers and nanoparticles: Various research approaches using liposomes, chitosan nanoparticles, and cell-penetrating peptides to ferry therapeutic peptides across the intestinal barrier.